Cargando…
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations
Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. To better understand neuroblastoma pathogenesis, here we analyze whole-genome, whole-exome and/or transcriptome data from 702 neuroblastoma samples. Forty percent of samples harbor at least one recurrent driver gene altera...
Autores principales: | Brady, Samuel W., Liu, Yanling, Ma, Xiaotu, Gout, Alexander M., Hagiwara, Kohei, Zhou, Xin, Wang, Jian, Macias, Michael, Chen, Xiaolong, Easton, John, Mulder, Heather L., Rusch, Michael, Wang, Lu, Nakitandwe, Joy, Lei, Shaohua, Davis, Eric M., Naranjo, Arlene, Cheng, Cheng, Maris, John M., Downing, James R., Cheung, Nai-Kong V., Hogarty, Michael D., Dyer, Michael A., Zhang, Jinghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560655/ https://www.ncbi.nlm.nih.gov/pubmed/33056981 http://dx.doi.org/10.1038/s41467-020-18987-4 |
Ejemplares similares
-
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020) -
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for
children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma
(ANBL00P3): a randomised, open-label, phase 3 trial
por: de Alarcon, Pedro A., et al.
Publicado: (2017) -
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group
por: DuBois, Steven G., et al.
Publicado: (2012) -
SequencErr: measuring and suppressing sequencer errors in next-generation sequencing data
por: Davis, Eric M., et al.
Publicado: (2021) -
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)